logo

Eagle Pharmaceuticals Inc (EGRX)



Trade EGRX now with
  Date
  Headline
6/24/2021 7:00:46 AM Eagle Pharma: FDA Maintains Priority Review For Vasopressin ANDA
6/17/2021 6:53:35 AM Eagle Pharma Submits Response To Complete Response Letter From FDA For Vasopressin
5/3/2021 6:53:26 AM Eagle Pharma Appoints Luciana Borio To Board
3/2/2021 6:55:01 AM Eagle Pharma Q4 Adj. Net Income $12.8 Mln Or $0.96/shr Vs. Income Of $6.7 Mln Or $0.48/shr Prior Year
2/2/2021 7:01:04 AM Eagle Pharma Gets Addl FDA Questions Regarding Vasopressin; Court Date Set For July 7 In Vasopressin Trial
2/1/2021 7:43:11 AM Eagle Pharma : US Court Postpones Feb 1 Vasopressin Trial Between Eagle And Endo Par
1/11/2021 7:12:32 AM Eagle Pharma Updates On Vasopressin Trial, Says Trial Date Postponed To Feb. 1 From Jan. 11 Due To COVID-19 Concerns
11/2/2020 6:55:19 AM Eagle Pharmaceuticals Q3 EPS $0.51 Vs Loss $0.17 Last Year
9/24/2020 7:00:44 AM Eagle Pharmaceuticals Commences $25 Mln Accelerated Share Repurchase
9/23/2020 6:54:16 AM Eagle Pharma's Partner, SymBio, Receives Approval Of TREAKISYM RTD Formulation, With Launch Expected In January 2021
8/19/2020 6:59:32 AM Eagle Pharma Announces Publication Of Preclinical Study Of Intranasal Dantrolene In Journal Of Alzheimer's Disease
8/10/2020 7:17:35 AM Eagle Pharma Q2 Loss Per Share $0.02; Adj EPS $0.59
5/11/2020 6:53:11 AM Eagle Pharmaceuticals Q1 Net Loss $2.9 Mln Or $0.21/shr Vs. Net Income $9.0 Mln Or $0.64/shr Last Year
3/30/2020 6:52:16 AM SymBio Pharmaceuticals Completes Patient Enrollment In Clinical Trial For TREAKISYM Rapid Infusion In Japan
3/2/2020 6:54:38 AM Eagle Pharma Q4 Non-GAAP EPS $0.49; GAAP EPS $0.07
2/10/2020 10:00:37 AM Eagle Pharma Receives Final FDA Approval For PEMFEXY, Pemetrexed for Injection